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7ORIGINAL RESEARCH Open AccessSynergism of peptide receptor-targeted Auger
electron radiation therapy with anti-angiogenic
compounds in a mouse model of neuroendocrine
tumors
Andreas Wicki1,2*, Damian Wild3, Vincent Prêtre1,2, Rosalba Mansi4, Annette Orleth1,2, Jean-Claude Reubi5,
Christoph Rochlitz1,2, Christoph Mamot6, Helmut R Mäcke4 and Gerhard Christofori7Abstract
Background: Neuroendocrine tumors are well vascularized and express specific cell surface markers, such as
somatostatin receptors and the glucagon-like peptide-1 receptor (GLP-1R). Using the Rip1Tag2 transgenic mouse
model of pancreatic neuroendocrine tumors (pNET), we have investigated the potential benefit of a combination of
anti-angiogenic treatment with targeted internal radiotherapy.
Methods: [Lys40(Ahx-DTPA-111In)NH2]-exendin-4, a radiopeptide that selectively binds to GLP-1R expressed on
insulinoma and other neuroendocrine tumor cells, was co-administered with oral vatalanib (an inhibitor of vascular
endothelial growth factor receptors (VEGFR)) or imatinib (a c-kit/PDGFR inhibitor). The control groups included
single-agent kinase inhibitor treatments and [Lys40(Ahx-DTPA-natIn)NH2]-exendin-4 monotherapy. For biodistribution,
Rip1Tag2 mice were pre-treated with oral vatalanib or imatinib for 0, 3, 5, or 7 days at a dose of 100 mg/kg.
Subsequently, [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 was administered i.v., and the biodistribution was assessed
after 4 h. For therapy, the mice were injected with 1.1 MBq [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 and treated with
vatalanib or imatinib 100 mg/kg orally for another 7 days. Tumor volume, tumor cell apoptosis and proliferation,
and microvessel density were quantified.
Results: Combination of [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 and vatalanib was significantly more effective
than single treatments (p < 0.05) and reduced the tumor volume by 97% in the absence of organ damage. The
pre-treatment of mice with vatalanib led to a reduction in the tumor uptake of [Lys40(Ahx-DTPA-111In)NH2]-
exendin-4, indicating that concomitant administration of vatalanib and the radiopeptide was the best approach.
Imatinib did not show a synergistic effect with [Lys40(Ahx-DTPA-111In)NH2]-exendin-4.
Conclusion: The combination of 1.1 MBq of [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 with 100 mg/kg vatalanib had
the same effect on a neuroendocrine tumor as the injection of 28 MBq of the radiopeptide alone but without any
apparent side effects, such as radiation damage of the kidneys.
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In neuroendocrine tumors, a range of different cell sur-
face markers is expressed preferentially [1,2]. The best-
known example is the somatostatin receptor subtype 2
(sst2), which is expressed on most neuroendocrine tu-
mors and can selectively be targeted by the somatostatin
analogue octreotide. Coupling of octreotide derivatives
to a radionuclide selectively induces cell death in som-
atostatin receptor-expressing tumor cells [3,4]. As a new
target, the glucagon-like peptide-1 receptor (GLP-1R)
has emerged. GLP-1R is highly expressed on insulino-
mas, gastrinomas, phaeochromocytomas, and other neu-
roendocrine tumors [1,5], and [Lys40(Ahx-DTPA-111In)
NH2]-exendin-4, a radiolabelled GLP-1 analogue, is spe-
cifically internalized in GLP-1R-expressing tumor cells
[6,7]. [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 is a radio-
pharmaceutical that consists of exendin-4 and the chela-
tor diethylene triamine pentaacetic acid (DTPA), which
in turn binds to 111indium, a γ-emitter and Auger emit-
ter. The dense shower of short-range Auger electrons
(range below 0.5 μm) released by 111In results in bio-
logical damage that is highly dependent on the location
of the decay site within the cell. Optimal Auger radiation
efficacy is obtained when Auger emitters are tightly
bound to DNA.
We have shown in the Rip1Tag2 mouse model of pan-
creatic neuroendocrine tumors (pNET) that [Lys40(Ahx-
DTPA-111In)NH2]-exendin-4 is suitable for molecular
imaging of NETs using single-photon emission com-
puted tomography (SPECT). pNETs could be detected
down to a size of 1 mm in diameter [7]. In a clinical
pilot study, we could localize occult insulinomas that
were not detectable using conventional imaging methods
[8]. In addition, the short-range Auger component of the
compound has a strong therapeutic effect in animal
models of human neuroendocrine cancer and resulted in
a 94% reduction of the tumor mass after the injection of
28 MBq of [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 in
the Rip1Tag2 mouse model [6]. However, the injection
of highly active [Lys40(Ahx-DTPA-111In)NH2]-exendin-4
in a dose of 28 MBq resulted in significant renal radi-
ation damage and consequent chronic renal failure [6].
Thus, targeted cytotoxic and radioactive pharmaceuti-
cals still have off-target effects on cells and tissues which
do not express the receptor for the drug. Therefore, tar-
geted therapy against neuroendocrine tumors may be
more efficient and better tolerated if a cytotoxic targeted
compound is combined with another targeted agent with
a different toxicity profile.
Neuroendocrine tumors are well vascularized [9]. Our
laboratory has previously shown that the expression of the
vascular endothelial growth factor (VEGF) is upregulated
in neuroendocrine tumors [10]. However, anti-angiogenic
treatment as a monotherapy is not a promising option,since vascular regrowth and increased local tumor inva-
sion after reversal of VEGF inhibition or through upregu-
lation of fibroblast growth factors (FGF) are serious
concerns [11-13]. Based on this, we instead hypothesize
that the combination of targeted therapy against neuroen-
docrine tumor cells themselves in conjunction with anti-
angiogenic compounds may increase the tumor response,
reduce off-target effects, and prevent tumor resistance as
encountered in monotherapy. As a second combination
strategy, we also investigated the [Lys40(Ahx-DTPA-111In)
NH2]-exendin-4 radiopeptide in combination with ima-
tinib, a small molecule inhibitor of c-kit and PDGFR. Ima-
tinib was shown to reduce the interstitial pressure inside
tumor tissue and may thus increase the delivery of the
radiopeptide to the tumor cells [14,15].
To test and compare these two drug combination strat-
egies, we treated a mouse model of human neuroendo-
crine cancer, the Rip1Tag2 mouse, with low-dose (1.1
MBq) [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 and either
vatalanib (PTK787/ZK-222584) or imatinib (STI571) for 7
days. For adequate controls, all agents including the radio-
peptide and the non-radioactive natIn-exendin-4 were ad-
ministered as monotherapy. Vatalanib is a potent inhibitor
of all three members of the VEGFR family (VEGFR-1 to 3).
Agents directed against VEGFR-2 have been shown to
increase drug uptake in human tumor cell xenografts in
athymic mice [16,17]. Vatalanib has proven effective in
several animal models of human cancer [18]. However,
vatalanib has also an effect on receptor tyrosine kinases
(RTKs) outside the VEGFR family: it inhibits the
platelet-derived growth factor receptor beta (PDGFR-β),
c-kit, and the colony stimulating factor 1 receptor (CSF1R,
also known as c-Fms), thus showing a certain overlap with
imatinib.
The combination therapy was performed in the Rip1-
Tag2 mouse model of pNET. These mice express the
simian virus (SV) large T antigen under the control of
the rat insulin promoter (Rip) and develop β-cell tumors
in a process of multi-stage carcinogenesis. Normal islets
and pNETs express both the VEGFR-1 and VEGFR-2 se-
lectively in CD31-positive endothelial cells [10]. Regard-
less of the tumor stage, the tumor cells themselves do
not express significant levels of VEGFR-1 or VEGFR-2.
PDGFR-β, the main target of imatinib in Rip1Tag2 mice,
is expressed on pericytes covering the larger vessels in
the tumor, but again not on the pancreatic tumor cells
[19,20]. Notably, Rip1Tag2 mice have been instrumental
in demonstrating the anti-tumor potential of a number
of targeted compounds, including vatalanib and imatinib
[21-24]. With this pre-clinical study, we provide evi-
dence that the combination of a targeted radiopeptide
with anti-angiogenic therapy provides a means of enhan-
cing tumor response and reducing therapy toxicity in
neuroendocrine tumors.
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Reagents and instrumentation
All chemicals were obtained from commercial sources and
used without further purification. 111InCl3 was purchased
from Covidien Medical (Petten, Netherlands). Analytical
HPLC was performed on a Metrohm HPLC system LC-
CaDI 22-14 (Herisau, Switzerland), and a Berthold LB
509 flow-through γ-detector (Berthold Technologies,
Bad Wildbad, Germany) with a Macherey-Nagel Nucleosil
120-3C-18 column (Düren, Germany). Matrix-assisted
laser desorption/ionization mass spectrometry (MALDI-
MS) measurements were done on aVoyager sSTR equipped
with a Nd:YAG laser (355 nm; Applied Biosystems,
Carlsbad, CA, USA). Quantitative γ-counting was per-
formed on a COBRA 5003 γ-system well counter (Packard
Instrument Company, Basel, Switzerland).
Peptide synthesis and radiolabelling
[Lys40(Ahx-DTPA)NH2]-exendin-4 was custom-synthetized
by Peptide Specialty Laboratories (Heidelberg, Germany).
The peptide conjugate was characterized by MALDI-MS
and RP-HPLC. An aliquot of 4 μg [Lys40(Ahx-DTPA)NH2]-
exendin-4 was dissolved in sodium acetate buffer (0.4 M/
pH 5.0), incubated with 100 MBq 111InCl3 at room
temperature for 30 min, and then subjected to a quality
control by analytical HPLC (eluents: A = 0.1% TFA in water
and B = acetonitrile, flow 0.75 ml/min; 0 min 95% A, 30
min 55% A, 32 min 0% A, 34 min 0% A, 37 min 95% A).
Mice
Phenotypic and genotypic analyses of Rip1Tag2 transgenic
mice in a C57Bl/6 background have been described previ-
ously [25]. Rip1Tag2 and wild type C57Bl/6 J mice were
used for organ toxicity studies. The animals were main-
tained and treated in compliance with the guidelines of
the Swiss Veterinary Office and the Cantonal Veterinary
office of Basel-Stadt (approval 2085 and 789).
Biodistribution, therapy, and toxicity study in
Rip1Tag2 mice
Male and female Rip1Tag2 mice, 19 to 32 g of weight and
11.6 ± 0.7 weeks old, were stratified according to their age
and randomly assigned to the different cohorts. For bio-
distribution studies, the Rip1Tag2 mice were treated with
oral vatalanib (dissolved in polyethylene glycol) or ima-
tinib (dissolved in water) at a dose of 100 mg/kg daily for
up to 7 days. Both vatalanib and imatinib were provided
by Novartis (Basel, Switzerland). Days (0, 3, 5, and 7 days)
after the beginning of vatalanib or imatinib treatment,
the mice were injected through the tail vein with 185 kBq
(10 ng peptide/2 pmol) [Lys40(Ahx-DTPA-111In)NH2]-
exendin-4 (111In-DTPA-exendin-4) in a 100-μl 1% human
serum albumin solution diluted in 0.9% NaCl. At 4 h after
injection, the mice were sacrificed under isoflurane andCO2 anesthesia. The organs, blood, and tumors were col-
lected, weighed, and the radioactivity in these samples was
determined using a γ-counter. The percentage of injected
activity (IA)/g tissue was calculated for each tissue.
To assess the efficacy of the combined therapy, Rip1Tag2
mice were injected once with 1.1 MBq (50 ng peptide/
10 pmol) 111In-DTPA-exendin-4 i.v. just before the oral
application of vatalanib or imatinib. Vatalanib and ima-
tinib were then administered at a dose of 100 mg/kg
daily for 7 days. On day 8, the mice were sacrificed, and
tumor diameters were measured with a grid (for small
tumors) or with a caliper (for large tumors). Afterward,
tumor volumes were calculated, assuming a spherical
shape of the tumors. Monotherapies with vatalanib,
imatinib, 1.1 MBq 111In-DTPA-exendin-4, and 40 pmol
non-radioactive [Lys40(Ahx-DTPA-natIn)NH2]-exendin-
4 (natIn-exendin-4) were performed as controls. Kidney
toxicity studies were carried out in Rip1Tag2 mice up
to 30 days and in C57Bl/6 J mice up to 6 months after the
termination of combination therapy and monotherapy. To
this end, Rip1Tag2 and C57Bl/6 J were sacrificed, and the
internal organs (pancreas, lungs, bowel, and kidneys) were
removed and analyzed histologically (H&E and PAS). In
addition, toluidine blue staining and electron microscopy
of the kidneys were performed.Histological analysis
The kidneys and tumors were fixed in 4% paraformalde-
hyde overnight at 4°C and embedded in paraffin. Immu-
nohistochemistry (including BrdU and TUNEL assays) on
paraffin sections were performed as described previously
[6]. For the staining of endothelial cells, rat anti-mouse
CD31 (BD Pharmingen, Allschwil, Switzerland) was used.Autoradiography
GLP-1 receptor autoradiography was used to quantify
the GLP-1 receptors in the mouse tumors in the pres-
ence or absence of vatalanib treatment. The Rip1Tag2
mice were treated with vatalanib as described before for
4 days and sacrificed on day 5. During necropsy, the tu-
mors were snap frozen on dry ice. Tumor sections (20-μm
thick) were incubated for 2 h at ambient temperature in
the presence of 32 pM [125I]-GLP-1 (2,000 Ci/mmol). The
incubation solution was 170 mM Tris-HCI buffer (pH 8.2)
containing 1% bovine serum albumin, bacitracin (40 μg/ml)
and MgCl2 (10 mM) to inhibit endogenous proteases.
Non-specific binding was determined by adding 100-nM
solution of unlabeled GLP-1. The incubated sections were
washed twice for 5 min in cold incubation buffer con-
taining 0.25% bovine serum albumin, then in buffer
alone, and dried quickly. Finally, the sections were ap-
posed to Biomax MR films (Kodak, Rochester, NY,
USA) and exposed for 1 week in X-ray cassettes.
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tified using a computer-assisted image processing system
[26,27]. Tissue standards for iodinated compounds were
used for this purpose.Radioligand internalization and nuclei isolation studies
A nuclei isolation kit (Nuclei EZ Prep Kit, Sigma-Aldrich
Chemie Gmbh, Steinheim, Germany) was used to separate
and quantify the amount of radioactivity stored in the nu-
clei [28]. The preparation was done according to the man-
ufacturer's instructions. The GLP-1 receptor-expressing
tumor cells were established from pancreatic tumors of
Rip1Tag2 mice, as described previously [7]. The cells were
seeded at a density of 2 × 107 cells in Petri dishes and in-
cubated overnight. Afterward, 25 pmol 111In-DTPA-exen-
din-4 (2.5 MBq) was added to the Petri dishes and
incubated at 37°C. The internalization was stopped at 2, 4,
and 24 h by removing the medium and by washing the
cells four times with 5-ml ice-cold phosphate-buffered sa-
line. Ice-cold nuclei EZ lysis buffer (2 ml) was added, and
the cells were scraped with a small bladed cell scraper.
The cell lysate was transferred to a separate 15-ml centri-
fuge tube and set on ice for 5 min. To collect the nuclei,
the cell lysate was centrifuged three times at 500 g for 5
min at 4°C. The culture medium, the clear supernatant
(cytoplasmatic supernatant), and nucleus pellets were
measured radiometrically with a γ-counter.Fluorescence microscopy
Subcellular localization of exendin-4 in mouse pancreatic
tumor cells was evaluated by fluorescence microscopy
using fluorescein-Trp25-exendin-4 (ANAWA, Zurich,
Switzerland) [29]. The GLP-1 receptor-expressing pancre-
atic tumor β-cells were freshly isolated from the Rip1Tag2
mice. They were cultured transiently and used within 6
weeks. Briefly, the cells were seeded into 12-well plates;
one glass coverslip was added for each well and incubated
overnight at 37°C. The day after, fluorescein-Trp25-
exendin-4 (30 pmol, 100 μl) was added, and the plates
were incubated for 2 h at 37°C. Immunofluorescence was
performed as described previously [30]. We used a lyso-
some marker, the rat monoclonal antibody [GL2A7]
against LAMP2 and an early endosome marker, the rabbit
polyclonal antibody against Rab5. The plates were washed
three times for 5 min per wash with HBS/Ca2+ and incu-
bated for 30 min at room temperature (RT) in a dark
room with the secondary antibodies (1:200 dilution in
HBS/Ca2+). After washing, the fluorescent nuclear stain
4′, 6′-diamidino-2-phenylindole dihydrochloride (DAPI;
Sigma-Aldrich, Saint Louis, MO, USA) was added, and
the plates were incubated for 2 min at RT. Immunofluor-
escence microscopy was performed on a LSM 510 META
confocal microscope (Zeiss, Oberkochen, Germany).Statistical analysis
Statistical analysis was performed using the GraphPad Prism
software (GraphPad Software Inc., San Diego, CA, USA).
The Kolmogorov-Smirnov test with Dallal-Wilkinson-Lillie
for p value was used to assess the normality distribution of
the data. Tumor volume and mass were calculated using
non-parametrical statistical analysis (Kruskal-Wallis test)
with Dunn's post-test. Proliferation, apoptosis, vessel density,
and peptide uptake were analyzed by parametric testing
(one-way ANOVA and Newman-Keuls post-test).
Results
Biodistribution of [Lys40(Ahx-DTPA-111In)NH2]-exendin-4
We investigated the effect of a combination treatment
with vatalanib and imatinib on the uptake of [Lys40(Ahx-
DTPA-111In)NH2]-exendin-4 in the pancreatic tumors
and other organs of Rip1Tag2 mice. Injection of vatalanib
led to a significant decrease of intratumoral peptide up-
take by 59.3% (86% IA/g versus 210% IA/g) within 7 days
(p < 0.001, Newman-Keuls post-test, Figure 1A). After
3 days of vatalanib treatment, there was already a (sta-
tistically not significant) trend to lower radiopeptide
uptake, and the uptake decreased further during the
following 4 days. Interestingly, the uptake in the kidney
was also reduced by 29.5% (p < 0.001, Newman-Keuls
post-test), while the uptake in all the other organs was
unaffected. In contrast, the pre-treatment of mice with
imatinib did not affect the uptake of the radiopeptide,
independent of the organ or time point analyzed
(Figure 1B).
Subcellular localization of [Lys40(Ahx-DTPA-111In)NH2]-
exendin-4
The subcellular distribution was assessed to determine
the internalization pathway and the amount of radio-
activity stored in the nuclei after 2, 4, and 24 h of con-
tinuous incubation of pancreatic tumor cells with [Lys40
(Ahx-DTPA-111In)NH2]-exendin-4. Immunofluorescence
co-staining of the cultivated pancreatic tumor cells of
Rip1Tag2 mice incubated 30, 60, 120, and 240 min with
fluorescein-Trp25-exendin-4 and stained with antibodies
against Rab5 (early endosome), Rab7 (late endosome), or
LAMP-2 (lysosome) indicates that cellular uptake of
exendin-4 is not strongly correlated with the endosomal
(Figure 2) or the lysosomal pathway (Figure 3). At 4 h of
incubation, the specific uptake into the cells was 9.78 ±
0.88% of the totally administered activity, increasing to
31.40 ± 5.04% at 24 h. Under these conditions, the nu-
clear uptake slightly increased over the time of incuba-
tion. After 2 and 4 h, only 1.0 ± 0.21% and 1.2 ± 0.3% of
specifically internalized [Lys40(Ahx-DTPA-111In)NH2]-
exendin-4 were localized in the cell nucleus, respectively.
This increased to 3.0 ± 1.0% at 24 h (mean ± SD of three
to six experiments).
Figure 1 Biodistribution of [Lys40(Ahx-DTPA-111In)NH2]-exendin-4. (A) Treatment of Rip1Tag2 mice with the VEGFR2-inhibitor vatalanib induces a
sharp decrease of [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 uptake into the tumor tissue and kidneys. In particular, specific tumor uptake diminishes by
more than 50% within the first 5 days of vatalanib treatment (**p < 0.01, *p < 0.05, Newman-Keuls post-test). (B) Pre-treatment of Rip1Tag2 mice with
imatinib does not significantly affect the specific uptake of [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 into the tumor tissue and organs.
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vatalanib treatment
We next wanted to investigate a possible interaction be-
tween the treatment of the Rip1Tag2 mice with vatalanib
and the expression of the GLP-1R. To this end, we pre-
treated Rip1Tag2 mice for 4 days with either 250 μl of
saline (control, n = 3) or with 100 mg/kg vatalanib p.o.
(interventional group, n = 4), followed by an administra-
tion of [Lys40(Ahx-DTPA-111In)NH2]-exendin-4. There-
after, the expression of the GLP-1R on pancreatic
tumors was quantified using autoradiography. The ex-
pression of the GLP-1R was not influenced by the treat-
ment with vatalanib (control 14,257 ± 7,070 dgm/min,
vatalanib-treated 14,176 ± 5,958 dgm/min, p = 0.98, two-sided t test, data not shown). Thus, the reduced uptake of
the radiopeptide, which is observed upon the treatment of
mice with vatalanib, is not due to a direct effect of vatala-
nib on the expression of the GLP-1R but rather to a re-
duced delivery of the compound to the tumor cells.
Therapeutic effects
The combined treatment regimen consisting of 1.1 MBq
[Lys40(Ahx-DTPA-111In)NH2]-exendin-4 and vatalanib
led to a significant reduction of the tumor volume with
a volume treated/volume control (T/C) ratio of 0.028
(2.8%) (Figure 4A, p < 0.0001 Kruskal-Wallis test). The
combination was superior to the single-agent treatments
with either vatalanib or 1.1 MBq [Lys40(Ahx-DTPA-111In)
Figure 2 Subcellular localization of fluorescein-Trp25-exendin-4
in cultivated tumor β-cells of Rip1Tag2 mice 2 h after injection.
Tumor beta-cells were incubated with fluorescein-Trp25-exendin-4
(A, green), anti-Rab5a (B, red, an anti-early endosome antibody),
and nuclear DAPI stain (C, blue). Fluorescein-Trp25-exendin-4 was
internalized into the cytoplasm and to a much lower degree into the
nuclei of the tumor beta-cells. However, no strong co-localization was
observed (D, merged picture). Scale bar, 10 μm.
Figure 3 Subcellular localization of exendin-4 in cultivated
tumor β-cells of Rip1Tag2 mice 2 h after injection. Tumor
beta-cells were incubated with FAM-exendin-4 (A, green), anti-Lamp-2
(B, red, an anti-lysosome antibody), and nuclear DAPI stain (C, blue).
Fluorescein-exendin-4 was internalized into the cytoplasm and into
the nuclei of tumor beta-cells. However, there was only a minimal
co-localization of FAM-exendin and Lamp-2 (D, merged picture).
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0.21 for 1.1 MBq of the radiopeptide, p < 0.05, Dunn's
test). The approximate 97% reduction of the tumor vol-
ume is similar to the effect observed after a single injec-
tion of 28 MBq [Lys40(Ahx-DTPA-111In)NH2]-exendin-4,
i.e., at 25-times higher radioactive dosage [6]. The
combined treatment modality led to the formation of
hemorrhagic lacunae in the centers of the tumors without
affecting morphologically normal islets (Figure 4C). The
treatment of mice with vatalanib alone or vatalanib
and the radiopeptide induced a significant decrease in
microvessel density as assessed by quantification of
CD31-positive blood vessels (median of 78/mm2 in the
natIn-exendin-4 group, 77/mm2 in the 1.1 MBq [Lys40
(Ahx-DTPA-111In)NH2]-exendin-4 group, 28/mm
2 for
vatalanib, and 34/mm2 for the combination therapy;
Figure 4B,D, p < 0.05, Newman-Keuls test).
In contrast, the combination of 1.1 MBq [Lys40(Ahx-
DTPA-111In)NH2]-exendin-4 and imatinib showed no
therapeutic benefit (Figure 5). The radiopeptide alonewas as efficient as the combination with imatinib (T/C
for 1.1 MBq [Lys40(Ahx-DTPA-111In)NH2]-exendin-4
0.21, T/C for imatinib 0.42, and T/C for the combination
0.18; Figure 5A,C). Imatinib had no apparent effect on
tumor-associated vessels, and the microvessel density
was comparable in all four cohorts (median number of
vessels between 78 and 81/mm2; Figure 5B,D).
Effect of combination therapy on tumor cell proliferation
and apoptosis
To investigate the mechanism underlying the tumor re-
sponse, we quantified tumor cell proliferation and apop-
tosis in all cohorts (Figures 6 and 7). The combination of
vatalanib and 1.1 MBq [Lys40(Ahx-DTPA-111In)NH2]-
exendin-4 did not significantly influence the rate of prolif-
erating cells as compared with the single-agent treatments
(31% of BrdU positive cells in the natIn-exendin-4 group as
compared to a median of 12% to 17% in all other groups;
Figure 6A,C). In contrast, the number of apoptotic tumor
cells in the combination group was increased fourfold in
comparison to the cohorts injected with natIn or 1.1 MBq
Figure 4 Therapeutic efficiency of combination therapy with [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 and vatalanib. (A) The combination
therapy reduces tumor burden by up to 97% (*p < 0.05, Kruskal-Wallis test) compared to the single-modality treatment. (B) The combination
therapy and monotherapy with vatalanib reduce the microvessel density significantly compared to monotherapy with [Lys40(Ahx-DTPA-111In)
NH2]-exendin-4 (p < 0.05, Newman-Keuls post-test). (C) H&E staining of tumors upon treatment. Histology confirms tumor regression in the
combination therapy arm, while normal islets are unaffected. (D) CD31 immunohistochemical staining on tumor sections. Vessels persist under
anti-angiogenic therapy, but vessel density is reduced. Size bars, 100 μm.
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fold in face of the vatalanib regimen (median number of
apoptotic cells/0.1 mm2 1.3 in the natIn-exendin-4 group,
1.2 in the 1.1 MBq [Lys40(Ahx-DTPA-111In)NH2]-exendin-
4 cohort, 1.7 in the vatalanib group, and 5 in the combin-
ation therapy cohort; Figure 6B,C; p < 0.0001 one-wayANOVA; p < 0.001 Newman-Keuls test for all comparisons
to the combined vatalanib + radiopeptide group).
The combination of imatinib with [Lys40(Ahx-DTPA-
111In)NH2]-exendin-4 did not induce a significant change
in the rate of proliferating or apoptotic cells as compared
to the injection of 1.1 MBq [Lys40(Ahx-DTPA-111In)
Figure 5 Therapeutic efficiency of combination therapy with [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 and imatinib. (A) The combination of
[Lys40(Ahx-DTPA-111In)NH2]-exendin-4 with imatinib has no additive effect on tumor burden (*p < 0.05, Kruskal-Wallis test). (B) The microvessel
density is not affected by the (combination) therapy with imatinib. (C) H&E staining of tumor sections after the completion of therapy. Tumor
necrosis can be seen under treatment with [Lys40(Ahx-DTPA-111In)NH2]-exendin-4. However, the combination treatment with imatinib does not
alter the tumor morphology. (D) The microvessel density is unaffected by treatment with [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 and/or imatinib.
Size bars, 100 μm.
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http://www.ejnmmires.com/content/4/1/9NH2]-exendin-4 alone (p > 0.05, Newman-Keuls test;
Figure 7A,B,C).
Taken together, the combination of vatalanib with [Lys40
(Ahx-DTPA-111In)NH2]-exendin-4 caused a sustained in-
duction of apoptosis that was superior to single-agent
treatment, exceeding a merely additive effect, while prolif-
eration is not significantly affected in comparison tosingle-agent application. Adding imatinib to the radiopep-
tide had no effect on either parameter.
Toxicity
To evaluate the toxicity of the combination treatments, we
injected both Rip1Tag2 and C57/Bl6 mice with [Lys40(Ahx-
DTPA-111In)NH2]-exendin-4 and treated both groups with
Figure 6 Proliferation and apoptosis of tumor β-cells treated with [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 and/or vatalanib.
(A) Treatment of mice with 1.1 MBq [Lys40(Ahx-DTPA-111In)NH2]-exendin-4, vatalanib, and the combination therapy induces a significant decrease
in tumor cell proliferation (***p < 0.001, Newman-Keuls post-test). However, there is no significant difference between the three interventional
groups. (B) In contrast, tumor cell apoptosis is significantly increased in the combined treatment group as compared to all the other groups
(***p < 0.001, Newman-Keuls post-test). (C) Immunohistochemical staining for BrdU (proliferation, top row) and TUNEL (apoptosis, bottom row).
Size bars, 100 μm.
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http://www.ejnmmires.com/content/4/1/9either 100 mg/kg vatalanib or 100 mg/kg imatinib orally for
7 days. The Rip1Tag2 mice were sacrificed after 8 and 30
days, while the C57/Bl6 mice were analyzed after 8, 30, and
60 days and 6 months. Since the transgenic expression of
the SV40 large T antigen continues in β-cells of treated
Rip1Tag2 mice, these mice form new tumors after the end
of the treatment, thus precluding long-term toxicity ana-
lysis in this model. Instead, long-term toxicity was assessed
in the C57/Bl6 mice.
As shown in Figure 1, significant uptake of the radio-
peptide is present in the pancreas, lungs, bowel, and kid-
neys. Furthermore, we had shown previously that the
kidneys are the dose-limiting organs when treating pan-
creatic tumors in Rip1Tag2 mice [6]. We therefore ana-
lyzed the toxicity at the given time points through
standard histology of the pancreas, lungs, bowel, and
kidneys. No toxicity could be observed. After toluidine
blue staining and electron microscopy of the kidneys,
again, we found no indication of acute or chronic radi-
ation damage or any other kidney pathology as assessed
by histology.Discussion
Vascular normalization is defined as a remodeling of tumor-
associated vessels into mature vessels, resulting in a more
physiological morphology and function. Normalization is a
well-established phenomenon, which occurs upon the treat-
ment of malignant tumors with anti-angiogenic compounds
and results in an improved oxygenation of the tumor, re-
duced vessel leakiness, and a normalized interstitial pressure
[16,31]. This was shown to increase the tumor's response to
either radiation therapy or cytostatic treatment. In a clinical
setting, however, the question is not only if normalization
occurs but also if the duration of the normalization lasts
long enough to provide a therapeutic window. Clinical trials
investigating the ‘window of opportunity’ are generally miss-
ing. Our data derived from biodistribution experiments in
the Rip1Tag2 mouse indicate that at least in the presented
experimental model, there is no such window. In our animal
model, vatalanib reduced the drug uptake into the tumor
cells, which may impair the efficacy of any targeted therap-
ies. The reduced tumor uptake can be explained by the sig-
nificant decrease of the microvessel density after treatment
Figure 7 Proliferation and apoptosis of tumor β-cells treated with [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 and/or imatinib.
(A) Proliferation of tumor beta-cells of Rip1Tag2 mice treated with [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 and [Lys40(Ahx-DTPA-111In)NH2]-
exendin-4 plus imatinib is reduced compared to the natIn-exendin-4 and the imatinib group (*p < 0.05, Newman-Keuls post-test). (B) However,
the combined treatment modality does not increase tumor cell apoptosis compared to the other groups (p > 0.05, Newman-Keuls post-test).
(C) Immunohistochemistry for proliferation (BrdU, top row) and apoptosis (TUNEL, bottom row) on the sections of Rip1Tag2 pancreas treated as
indicated on the graph. Size bars, 100 μm.
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http://www.ejnmmires.com/content/4/1/9with vatalanib. This is in line with previous data, indicating
that anti-angiogenic treatments indeed significantly reduce
the uptake of targeted therapies in patients and in several
animal models [32-36].
Interestingly, in a phase-three trial of sunitinib, there
was an improvement of the overall and the progression-
free survival in patients with pNET [37]. Like vatalanib,
sunitinib is a multi-targeted tyrosine kinase inhibitor
blocking all PDGF-Rs and VEGFRs. Thus, combination
of targeted radiopeptides with anti-angiogenic compounds
is a particularly attractive option because radiopeptide
monotherapies such as [90Y-DOTA-Tyr3]-octreotide and
[177Lu-DOTA-Tyr3]-octreotate showed an excellent ob-
jective response rate and progression-free survival in
patients with neuroendocrine tumors [3,4]. In addition,
cediranib, a highly potent inhibitor of VEGFR tyrosine
kinase activity, showed a radiosensitizing effect in combin-
ation with radiotherapy [38]. In contrast, [177Lu-DOTA-
Tyr3]-octreotate was shown to be less effective when com-
bined with the mTOR inhibitor everolimus (RAD001,
Novartis) in a rat model of pancreatic cancer [39]. Alongthe same line, no synergistic effect of adding imatinib was
observed in our pre-clinical trial. This underlines the im-
portance to choose adequate combination partners for
radiopeptide therapy. Since both vatalanib and imatinib
inhibit PDGFR, this argues that the main synergistic effect
of the combination therapy is mediated via the inhibition
of the VEGF receptors. For a potential clinical combination
therapy, VEGFR inhibitors may thus be more suitable part-
ners for radiopeptides than other kinase inhibitors.
Unfortunately, the value of the Rip1Tag2 mice as a long-
term treatment model is rather limited. Because of the on-
going expression of the large T antigen in β-cell islets, these
mice continue to form new tumors during their whole life-
span [25]. In a previous set of experiments, our group had
shown that monotherapy with vatalanib has a persistent ef-
fect on the vessel formation for up to 21 days in the Rip1-
Tag2 model. However, there is no further decrease of
microvessel density when the treatment is prolonged [40].
The reduction of the tumor volume was similar to that for
a 1-week and a 3-week course of therapy. Therefore, we
have not performed prolonged treatment in this study.
Wicki et al. EJNMMI Research 2014, 4:9 Page 11 of 13
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targeted Auger emitter radiation therapy with an anti-
angiogenic compound has a synergistic effect on the
pancreatic tumors of the Rip1Tag2 transgenic mice. Of
the many treatment regimens tested in the Rip1Tag2
mice, including genetic ablation or sequestration of tumor-
and angiogenesis-promoting factors (VEGF, insulin-like
growth factor II, and fibroblast growth factors), and clas-
sical chemotherapy, the combined treatment with [Lys40
(Ahx-DTPA-111In)NH2]-exendin-4 and vatalanib is one of
the most efficient, with up to 97% smaller tumor volume
in the interventional group, compared to 67% to 91% in
previous studies [6]. These results are comparable to those
achieved using a 25-fold higher dose of [Lys40(Ahx-DTPA-
111In)NH2]-exendin-4 in the absence of an anti-angiogenic
compound [6].
Our results indicate that Auger radiation in combin-
ation with the inhibition of VEGF receptors is likely re-
sponsible for the massive induction of tumor cell
apoptosis. Importantly, this effect is tumor cell specific
since an extensive toxicological evaluation did not pro-
vide any evidence of acute or chronic organ damage with
the combination treatment. Thus, the combination with
an anti-angiogenic drug that has a different toxicity
profile than the radiopeptide reduces the amount of
[Lys40(Ahx-DTPA-111In)NH2]-exendin-4 and is a more
nephroprotective treatment. This is relevant because
kidney toxicity is a main limitation of targeted radio-
peptide therapy [4,41]. Collectively, our data support
the contention that VEGFR inhibition can enhance ra-
diation response in tumors [38]. Although the mecha-
nisms underlying the radiosensitizing effect of vatalanib
remain unclear, it is conceivable that enhanced apop-
tosis together with reduced proliferation of tumor cells
may reduce intratumoral oxygen demand to a level that
can still be met by the damaged tumor vasculature and
thereby avoid a hypoxic state in the tumor that would
reduce the efficacy of [Lys40(Ahx-DTPA-111In)NH2]-
exendin-4. Auger electron emitters such as 111In are
known to damage the DNA if they decay close to the
cell nucleus, and the potential advantage in targeted
radionuclide therapy is its short range of nanometers to
micrometers which is sufficient for damaging the DNA
in tumor cells while sparing surrounding normal cells
[42]. Goddu et al. estimates that the radiation dose to
the nucleus in a single cell is increased twofold if 111In
is located in the cytoplasm compared to the cell surface
and about 20-fold if located in the nucleus [43]. Cai
et al. used a three-dimensional cell cluster model,
which is a more appropriate model for the microdose
estimation of tumors in vivo. They showed that the es-
timated radiation dose to the nucleus is increased only
twofold if 111In is located in the nucleus compared to
the cytoplasm and cell surface [44]. In our experimentalmodel, less than 5% of the internalized activity accumu-
lated in the nucleus. Therefore, the therapeutic effect of
1.1 MBq [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 can
be explained by the very high tumor uptake of 287 ±
62% IA/g tumor [7]. A rough calculation allows the es-
timation that approximately 9 mBq is taken up by a sin-
gle tumor cell (4,460 kBq/g tumor, 1-gram wet weight
is assumed to contain 5 × 108 tumor cells). This value
appears low, but is higher than what Chen et al. found
using an 111In-NLS-HuM195 antibody targeting the
CD33 antigen overexpressed on acute myeloid leukemia
cells [45]. In cell culture, they found a major reduction
of cell survival with 1.48 mBq 111In/cell if about 50% of
111In-NLS-HuM195 is located in the nucleus.
Conclusions
In our study, we found that the combination of 1.1 MBq of
[Lys40(Ahx-DTPA-111In)NH2]-exendin-4 with 100 mg/kg
oral vatalanib for 7 days had the same effect on a neuroen-
docrine tumor as the single-injection of 28 MBq of the
radiopeptide alone. Our data suggest that this co-treatment
is synergetic and at the same time reduces side effects,
such as radiation damage of the kidneys. Many neuroendo-
crine tumors have a high density of tumor-associated
vessels, and thus our model might serve as paradigm,
highlighting the potential of a combined treatment against
neuroendocrine tumor vessels and tumor cells alike. In
contrast, the addition of imatinib did not result in any
additive or synergistic therapeutic effect.
Based on these results, we deem it warranted to evalu-
ate this approach in a clinical trial. A clinical confirm-
ation of these data will hopefully help advance a more
efficient therapy of neuroendocrine tumors with less off-
target effects in the future.
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